The Boston biotech founded by Harvard professor David Sinclair is testing whether cellular reprogramming can turn back the ...
Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of ...
In 1962, a pediatric neurology resident at Columbia's Neurological Institute and his colleagues in the College of Physicians ...
Scientists at The University of Texas at Austin have developed a revolutionary gene-editing method using bacterial retrons ...
We are now in the second great wave of the genetic revolution, not defined by reading the human code of life, but by rewriting it.
Fractyl Health announced a first-in-human trial for RJVA-001, targeting T2D and obesity, pending regulatory approval by 2026. Fractyl Health, Inc. has announced the submission of the first module of ...
RheumaGen, Inc., a cell and gene therapy company engineering a new class of therapeutics to cure common autoimmune diseases, today announced groundbreaking preclinical research that supports a nearly ...
The goal of gene therapy is to permanently cure hereditary diseases. One of the most promising technologies for this is the ...
Gene therapy delivering protective vascular endothelial growth factor C into kidney filters reduced early diabetic kidney ...
After telegraphing an investigation in November, the FDA has moved to restrict the use of bluebird bio’s gene therapy Skysona in certain patients. The FDA has updated Skysona’s indication, allowing it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback